Category: Cardiac Rhythm ManagementSyndicate content

CorMatrix lands FDA win, touts 1st human implant of CanGaroo surgical pouch

August 28, 2014 by Arezu Sarvestani

CorMatrix secure FDA clearance for its CanGaroo ECM envelope for use with implantable cardiac devices and touts 1st human use in a patient at Ohio's Cleveland Clinic.

CorMatrix lands FDA win, touts 1st human implant of CanGaroo surgical evelope

Georgia medical device maker CorMatrix touted an FDA win this month, landing regulatory clearance for its CanGaroo surgical envelope for securing implantable cardiac devices.

Press Release: CorMatrix reports FDA clearance of CorMatrix CanGaroo ECM Envelope

August 28, 2014 by MassDevice

Press Release: CorMatrix reports FDA clearance of CorMatrix CanGaroo ECM Envelope

Roswell, Georgia – CorMatrix Cardiovascular announced today that it has received U.S. Food and Drug Administration (FDA) clearance to market the CorMatrix CanGaroo ECM Envelope for use with cardiac implantable electronic devices (CIED's) including pacemakers and implantable cardioverter defibrillators (ICD's).

Medtronic launches personalized heart rhythm therapy trial

August 27, 2014 by Arezu Sarvestani

Medtech titan Medtronic enrolls the 1st patients in the AdaptResponse clinical trial to evaluate its adaptive cardiac rhythm management technology.

Medtronic launches personalized heart rhythm therapy trial

Medtronic (NYSE:MDT) touted the launch of its AdaptResponse trial, the largest study of its kind evaluating the company's AdaptivCRT algorithm for personalizing cardiac resynchronization therapy in treatment of heart failure.

Judge agrees to toss ex-Biosense rep's suit in non-compete row with St. Jude Medical

August 27, 2014 by Brad Perriello

A federal judge agrees to toss a lawsuit filed against Johnson & Johnson's Biosense Webster by a former sales rep and her new employer, St. Jude Medical.

Judge agrees to toss ex-Biosense rep's suit in non-compete row with St. Jude Medical

Medtronic's personalized pacemaker wins FDA approval

August 25, 2014 by Arezu Sarvestani

FDA regulators approve Medtronic's new Viva CRT-P adaptive cardiac pacemaker for treatment of heart failure or atrioventricular block.

Medtronic's personalized pacemaker wins FDA approval

Medtronic (NYSE:MDT) won FDA approval for its Viva CRT-P cardiac resynchronization therapy-pacemaker, which features proprietary software to adjust its pacing parameters to a patient's heart rhythms minute-by-minute.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Press Release: Medtronic Viva cardiac resynchronization therapy-pacemaker now available in U.S.

August 25, 2014 by MassDevice

AdaptivCRT algorithm customizes therapy for heart failure patients and improves their response rates.

Press Release: Medtronic Viva cardiac resynchronization therapy-pacemaker now available in U.S.

MINNEAPOLIS - Medtronic, Inc. (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) approval of its newest cardiac resynchronization therapy-pacemaker, Viva® CRT-P, for indicated patients with heart failure or atrioventricular (AV) block.

AliveCor lands FDA win for at-home afib diagnosis

August 21, 2014 by Arezu Sarvestani

FDA regulators grant AliveCor new clearance for an at-home heart rhythm test for diagnosing asymptomatic atrial fibrillation.

AliveCor lands FDA win for at-home afib diagnosis

AliveCor hit a major turning point for its smartphone-based ECG technology with FDA clearance for a new algorithm that helps patients diagnose their own heart rhythms.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp